Werewolf Therapeutics is an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments designed to focus the body's immune response to selectively target cancer. Werewolf's proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential. Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/20/19 | $56,000,000 | Series A |
Arkin Bio Ventures DC Investment Partners Longwood Fund  MPM Capital Taiho Ventures UPMC Enterprises | undisclosed |
